



MARKET RELEASE

11 July 2017

DIMERIX LIMITED

TRADING HALT

The securities of Dimerix Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Thursday, 13 July 2017 or when the announcement is released to the market.

Security Code: DXB

Jeremy Newman
Senior Adviser, Listings Compliance (Perth)



11 July 2017

Ms Elizabeth Harris
Senior Adviser, Listings Compliance (Perth)
ASX Compliance Pty Ltd
Level 40 Central Park, 152-158 St George's Terrace
Perth WA 6000

Dear Ms Harris

The directors of Dimerix Limited hereby request a trading halt of the company's securities.

The trading halt is necessary as the Company has received results from its Phase 2 trial of DMX-200 in patients with Chronic Kidney Disease which are in the process of being compiled for release to the market.

The trading halt is requested until an announcement is made to the market which is expected prior to the opening of trading on Thursday 13 July 2017.

The company is not aware of any reason why the trading halt should not be granted.

Yours faithfully

A handwritten signature in blue ink, appearing to read "I. Hobson".

Ian Hobson
Company Secretary